Numbers don’t lie
Not like we needed even more evidence that Lilly is now a GLP-1 first insulin second company here are some numbers from today’s earnings release all of which are year to date sales
Trulicity $2.98 Billion
Humalog $1.2 Billion
Humulin $637 million
Basaglar $457 million
Sales of the three insulin products added together still do not match what Trulicity is doing. Want more reasons why GLP-1’s are getting all the attention and not just because sales are increasing, patent life is longer and commodization has yet to occur – take a look at . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.